The estimated Net Worth of Malcolm Fairbairn is at least $1.22 Million dollars as of 19 May 2021. Malcolm Fairbairn owns over 10,000 units of Tff Pharmaceuticals Inc stock worth over $21,700 and over the last 5 years Malcolm sold TFFP stock worth over $1,195,500.
Sign up
Malcolm Fairbairn TFFP stock SEC Form 4 insiders trading
Malcolm has made over 2 trades of the Tff Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Malcolm bought 10,000 units of TFFP stock worth $89,500 on 19 May 2021.
The largest trade Malcolm's ever made was selling 75,000 units of Tff Pharmaceuticals Inc stock on 11 November 2020 worth over $1,195,500. On average, Malcolm trades about 21,250 units every 47 days since 2020. As of 19 May 2021 Malcolm still owns at least 10,000 units of Tff Pharmaceuticals Inc stock.
You can see the complete history of Malcolm Fairbairn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Malcolm Fairbairn's mailing address?
Malcolm's mailing address filed with the SEC is 2600 VIA FORTUNA, SUITE 360, , AUSTIN, TX, 78746.
Insiders trading at Tff Pharmaceuticals Inc
Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher, and Harlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.
What does Tff Pharmaceuticals Inc do?
tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.
What does Tff Pharmaceuticals Inc's logo look like?
Complete history of Malcolm Fairbairn stock trades at Tff Pharmaceuticals Inc
Tff Pharmaceuticals Inc executives and stock owners
Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Glenn R. Mattes,
Pres, CEO & Director -
Kirk Allen Coleman,
CFO, Treasurer & Sec. -
Christopher Cano,
COO & VP of Bus. Devel. -
Paul F. Manley,
Head of Regulatory Affairs -
Dr. Anthony J. Hickey Ph.D.,
Chief Scientific Officer -
Dr. Dale Christensen,
Director of Clinical Devel. -
Dr. James Brian Windsor Ph.D.,
Chief Science Officer & Director -
Dr. James Brian Windsor,
Chief Science Officer & Director -
Malcolm Fairbairn,
Director -
Zamaneh Mikhak,
Chief Medical Officer -
Robert S Mills,
Director -
Glenn R. Mattes,
President and CEO -
James Brian Windsor,
Chief Science Officer -
Aaron G.L. Fletcher,
Director -
Randy H Thurman,
Director -
Brandi Roberts,
Director -
Stephen Rocamboli,
Director -
Therapeutics, Inc. Lung,
10% owner -
Michael A Patane,
Director -
Catherine Chai Zon Lee,
Director -
Christopher Cano,
Chief Operating Officer -
Harlan F Weisman,
President and CEO -
Kirk Allen Coleman,
Chief Financial Officer -
Capital L P Double Black Di...,
-
Thomas Braxton King,
Director